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Abstract
Background: Patient-reported outcomes (PROs), such as health-related quality of life (HRQL) are increasingly used
to evaluate treatment effectiveness in clinical trials, are valued by patients, and may inform important decisions in the
clinical setting. It is of concern, therefore, that preliminary evidence, gained from group discussions at UK-wide
Medical Research Council (MRC) quality of life training days, suggests there are inconsistent standards of HRQL
data collection in trials and appropriate training and education is often lacking. Our objective was to investigate these
reports, to determine if they represented isolated experiences, or were indicative of a potentially wider problem.
Methods And Findings: We undertook a qualitative study, conducting 26 semi-structured interviews with research
nurses, data managers, trial coordinators and research facilitators involved in the collection and entry of HRQL data
in clinical trials, across one primary care NHS trust, two secondary care NHS trusts and two clinical trials units in the
UK. We used conventional content analysis to analyze and interpret our data. Our study participants reported (1)
inconsistent standards in HRQL measurement, both between, and within, trials, which appeared to risk the
introduction of bias; (2), difficulties in dealing with HRQL data that raised concern for the well-being of the trial
participant, which in some instances led to the delivery of non-protocol driven co-interventions, (3), a frequent lack of
HRQL protocol content and appropriate training and education of trial staff, and (4) that HRQL data collection could
be associated with emotional and/or ethical burden.
Conclusions: Our findings suggest there are inconsistencies in the standards of HRQL data collection in some trials
resulting from a general lack of HRQL-specific protocol content, training and education. These inconsistencies could
lead to biased HRQL trial results. Future research should aim to develop HRQL guidelines and training programmes
aimed at supporting researchers to carry out high quality data collection.
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Introduction
Patient-reported outcomes (PROs), such as health-related
quality of life (HRQL) are increasingly used to evaluate
treatment effectiveness in clinical trials [1]. Patients value
information on their HRQL [2,3] and may use it to inform
complex healthcare decisions [4], for example, choosing
between treatments offering similar survival rates [5], or
selecting an intervention with the most acceptable side-effect
profile [6]. HRQL trial results may inform decision-making in the
clinical setting [7], support pharmaceutical labeling claims [8]
and influence healthcare policy [9]. Thus, it is important that
trialists take steps to ensure that their HRQL data are valid,
reliable and free from bias.
Reducing the risk of bias is a prime consideration of trial
design and common methods of improving the quality of trials
may include appropriate randomisation and allocation
concealment, adequate blinding, minimizing loss to follow up
and the use of intention to treat analysis [10]. Other potential
sources of bias may still arise, however, such as
inconsistencies in the way outcome data are collected across
study sites. To mitigate the risk of this kind of bias, PRO trial
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data should be collected using standardised methods [8].
Ideally, the same data collection processes should be applied
at all study sites and across all study groups; with the
standardised methods that will be employed during the trial
clearly outlined in the study protocol, and communicated to
research staff through in-house training and supporting trial
documentation, for example, standard operating procedures
(SOPs) [10].
It is of concern, therefore, that preliminary evidence, gained
from UK-wide group discussions at quality of life training days
run by the MRC, Midland Hub for Trials Methodology, suggests
there are inconsistent standards of HRQL data collection in
trials, and related trial protocol content, training and education
is often lacking. Furthermore, researchers have reported
problems when encountering HRQL data which raises concern
for the well-being of the participant in some way (hereafter
referred to as ‘concerning’ data), which may occur on collection
of the questionnaire from the patient, or at the point of data
entry. When faced with ‘concerning’ data - typically represented
by extreme HRQL scores, or contained within unprompted
additional comments recorded on the questionnaire - some
researchers reported administering ad-hoc, off-protocol, co-
interventions to help improve HRQL: for example, facilitating
referral of a patient suffering with depression to a counseling
service. Co-interventions, i.e. “any intervention other than the
experimental maneuver that alters the frequency of a trial’s
outcome of interest” [11], may lead to bias if they are
administered differently across trial arms. Unless co-
interventions in a trial are formally reported and the associated
costs captured, under- or over-estimates of clinical efficacy and
cost-effectiveness may result.
Any threat to the integrity of PRO trial data should be
comprehensively investigated. Therefore, in the absence of
existing research, we conducted a qualitative study to explore
the experiences and opinions of research nurses and trialists
involved in the collection and inputting of PRO data in UK-
based clinical trials, with a specific focus on HRQL. Our
objective was to investigate reported inconsistencies in HRQL
data collection in clinical trials, to determine if they represented
isolated experiences, or were indicative of a potentially wider
problem.
Methods
Our study employed a qualitative research design; semi-
structured interviews were used to gather data from
researchers involved in the collection and entry of HRQL data
in clinical trials. A favourable ethical review was received from
the West Midlands Research Ethics Committee (ref no 12/wm/
0068). All participants gave written informed consent prior to
taking part in the study. Interview discussions were digitally
recorded, professionally transcribed (verbatim) and
anonymised prior to analysis. The anonymised transcripts were
stored electronically in accordance with the University of
Birmingham ‘Code of Practice for Research’ and will be
preserved in an accessible form for ten years prior to being
securely deleted. The interviews and primary analysis were
conducted by DK, supported by regular meetings with HD, JI
and MC, primarily concerned with promoting reflexivity.
Participants and Setting
Researchers were recruited across the following sites: one
primary care NHS trust, two secondary care NHS trusts and
two clinical trials units. These sites were selected to facilitate
recruitment of researchers with a variety of professional
backgrounds. All sites were based in the UK. During
recruitment, information about the study was cascaded to all
research nurses, research facilitators, data managers and trial
coordinators at these sites, through their respective research
management structures. Individuals were asked to register
their interest with DK, who determined eligibility, provided
additional information about the study and answered any
further questions. Potential participants were deemed eligible if
they reported prior experience of involvement in HRQL data
collection or data entry within a clinical trial, with direct
experience of handling HRQL questionnaires. We sought
maximum variation with regard to trial experience (e.g.
specialist area, length of experience, primary/secondary care
setting) during recruitment, in order to capture viewpoints from
a range of researcher roles. Recruitment continued within each
distinct staff group until there was data saturation, i.e. no new
data was provided by the most-recent batch of interviews from
that group.
Interviews
In-depth semi-structured interviews were conducted by DK,
following Fielding’s guidelines [12]. A topic guide was
developed (Interview Topic Guide S1), comprising open-ended
questions that maintained a focus on the research aims, but
which was sufficiently flexible to allow participants to raise
different issues that were important to them. TK piloted
questions amongst eight researchers, including three research
nurses and five clinical trialists, who held trial management or
senior research nurse roles in oncology, osteoarthritis or injury
rehabilitation research. The final version of the topic guide
included questions on: (1) the experience of the participant
regarding HRQL data collection or inputting; (2) the HRQL-
specific trial guidelines and/or training that participants had
encountered during their research careers; (3) whether
‘concerning’ data had been encountered, and if so, how it was
dealt with; and, (4) the challenges associated with HRQL data-
collection and areas in need of improvement. The topic guide
evolved alongside data analysis, ensuring that subsequent
interviews explored themes arising from ongoing analysis.
Therefore, the research remained participant-led and allowed
emerging hypotheses to be tested and challenged in
subsequent interviews [13]. All interviewees were sent a
summary of their interview for checking. One participant
suggested minor alterations regarding the way in which an
administrative element of their trial had been interpreted.
Corrections were made and were subsequently approved by
the participant. All other interview summaries were approved
without amendment.
Inconsistencies in Quality of Life Data Collection
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Analysis
Ongoing and iterative content analysis drew upon principles
of grounded theory [14] and utilised both constant comparison
[13] and deviant case analysis [15]. Interview transcripts were
examined in depth by DK (immersion), prior to first cycle
coding. A mixture of in-vivo, process and initial coding methods
were utilised during the first cycle [16]. Focused, axial and
theoretical coding was employed during subsequent cycles
[16]. The aim was to construct a hierarchical network of
themes, which captured the essence of the data and facilitated
the development of a core theory. All interviews were analysed
using the Dedoose (© 2011 SCRC) qualitative data analysis
software. HD, JI and MC formally reviewed a subset of 10% of
the transcripts to enhance the credibility and trustworthiness of
coding and interpretation. Further, regular, meetings were held
to discuss the emerging data. Decisions were made about
which developing hypotheses needed to be tested in
subsequent interviews, and proposed changes to the topic
guide were agreed or rejected. Finally, HD, JI, MC and DK met
to agree on the final themes and core theory.
Results
Characteristics of Interviewees
26 researchers were interviewed. Interviewees included
research nurses, trial coordinators, data managers and
research facilitators, and were drawn from all five of the
recruitment sites in the study. The characteristics of the
interviewees are presented in Table 1. Interviews lasted on
average 38 minutes.
Table 1. Characteristics of interviewees.
Participants Characteristics
Research Nurses  
Sample n=16
Experience as a Research
Nurse, Mean (range), in years 6 (0.25-16)
Total Nursing Experience, Mean
(range), in years 18 (2-30)
Specialist Areas, n (%)
General medicine (n=7, 44%); Neurology (n=2,
12%); Orthopaedics (n=3, 19%); Oncology
(n=3, 19%); Ophthalmology (n=1, 6%)
Trialists  
Sample n=10
Research Roles, n (%) Trial coordinator (4, 40%); Data Coordinator (4,40%); Research Facilitator (2, 20%)
Experience in Research Role,
Mean (range), in years 2.3 (0.75-4)
Specialist Areas, n (%)
Gen medicine (4, 40%); Elderly care (1, 10%);
Obstetrics (2, 20%); Orthopaedics (1, 10%);
Oncology (1, 10%); Rheumatology (1, 10%)
Total Sample
n=26; 15 Primary care (58%); 11 secondary
care (42%); mean experience in a research
role = 4.62yrs(range 0.25-16)
doi: 10.1371/journal.pone.0076625.t001
Overview of Themes
Interviewee responses generated four main themes: (1)
apparent inconsistency in HRQL data collection, (2) identified
difficulties in dealing with ‘concerning’ HRQL data, (3) a
perception that HRQL data collection could be associated with
considerable researcher burden and, (4) identification of
deficiencies in HRQL data collection management and areas in
need of improvement.
Inconsistency in HRQL data collection
Interviewees suggested that HRQL data-collection is
inconsistently managed between, and within, trials, both in
terms of the logistics of HRQL measurement and in the
handling of missing data.
Logistical issues.  Interviewees reported considerable
variation in the way in which different individuals administered
HRQL questionnaires within/between trials. For example, the
levels of privacy afforded to trial participants whilst they
completed the questionnaire appeared to vary within/between
trials, depending on location and staff concerned.
“If they’re an in-patient… they’ve got time to
sit and do it within their space and privacy.
Within primary care if you’re in a GP surgery
and you’ve got loads of clinics going on… I’d
like to give him a private room to go into and
say “please sit in there, please take your time,
please do this”, and, but it doesn’t happen. Very
often they actually will fill them out in reception
area.” [participant 3; research nurse]
“I do know colleagues that will fill them out
and ask the questions while… you know, quite
loudly, in front of their relatives and in front of,
you know, not in a soundproof room or in a
corner.” [participant 15; research nurse]
When the HRQL assessment was planned to coincide with a
participant’s clinic appointment, there was inconsistency
reported with regard to the timing of questionnaire completion
and interviewees were unsure about the optimal timing.
“There’s no guidance on when to do the
quality of life quite often, and I don’t know
where it is best to be done.” [participant 3;
research nurse]
“It’s hit and miss whether it’s before or after
[the clinic appointment].”[participant 6; research
nurse]
They also held differing views about the level of assistance
that should be given to their participants during questionnaire
completion. Some highlighted the importance of having a
researcher present in order to answer the participant’s
questions, whilst others advocated self-completion without
advice.
“I give the person the questionnaire and then
um ask [the] patient to fill it in themselves yeah,
Inconsistencies in Quality of Life Data Collection
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without me helping them.” [participant 1;
research nurse]
“I firmly believe that… the patient is giving up
their time to partake in our research, and that I
should be available… while they’re in there.
Because quite a few patients actually panic a
bit about, ‘I don’t understand this question,’ or,
you know, ‘is that right?’…” [participant 4;
research nurse]
Missing data.  Asking about the interviewees’ approach to
identifying, and dealing with, missing HRQL data elicited a
range of differing responses. Some researchers reported
routinely checking completed questionnaires for missing data,
some described both checking for missing data and also
examining the content of the answers for scoring errors, whilst
others did not check the questionnaires at all.
“We do sit there with the patient and just go
through it before they leave, just in case [there
is] anything they’ve missed out.” [participant 11;
research nurse]
“We as research nurses always check the
answers to see what they’ve put.” [participant
17; research nurse]
“I was taught, in, in my early years of
research… you give that form to a patient in an
envelope and they complete it and put it in, and
you don’t look at it.” [participant 15; research
nurse]
This variation in approach was also evident when
interviewees discussed methods of dealing with missing data.
There were not only significant differences between trials, there
were examples of differing approaches adopted for different
trial outcomes, and even opposing arms, of the same trial,
some of which risked the introduction of bias.
“There are specific questions within the
[study] questionnaire that we do need to be
answered… if they’re sort of left off, then we
have to try and get in touch with the
participants, ring them and ask them those
questions over the phone... if they’ve completed
the… necessary questions but then they’ve left
the quality of life [questions] blank, we don’t
have to chase them for that… I struggle a bit
with that… I think you should make as much
effort to get the responses to those as you
should to get responses to the primary outcome
really.” [participant 20; trial coordinator]
“If they go into our control group… they’re not
gonna have any personal contact, then [the
questionnaire] will go back out in the post with
just a letter, sort of, saying, ‘Oh, you
accidentally missed out this one,’ and, er, and
hopefully they’ll return it back… if they’re put
into an exercise, erm, intervention, then they do
get seen by [a research facilitator]. I’ll ask her to
take the questionnaire with her… she’ll help
them to fill it in.” [participant 25; trial
coordinator]
Dealing with ‘concerning’ data
Research nurses (and to a lesser extent data managers)
discussed discovering, and subsequently dealing with,
‘concerning’ HRQL data, i.e. that which raised concerns about
a trial participant’s well-being. Just over half (n=15, 58%) of our
interviewees reported that they had encountered ‘concerning’
HRQL data at some point during their research careers
(participants 2, 5, 6, 8, 10, 16-21 and 23-26). Interviewees
were asked whether any particular HRQL information gave rise
to concerns. The most common responses were; a significant
reduction in quality of life, for example, evidence of low self
esteem or depression, or an indicated risk of self-harm or
suicide.
“The difficult bit is when you have a comment
section at the end… some patients choose that
to [describe] something that’s happened to
them… sometimes about erm depression and if
you’ve read that, then you should act on it.”
[participant 5; research nurse]
“The sorts of things that I’ve found
concerning have been when people… have
done sort of quite long rambling sort of letters,
talking about… the struggles that they’re going
through, and erm that nobody’s doing anything
and nobody’s helping them and what are they
supposed to do and does something really bad
have to happen… for anything to change… you
know ‘it’s all hopeless, what’s the point’ sort of
thing.” [participant 20; trial coordinator]
Recognition and frequency.  Interviewees reported that
‘concerning’ data presented in three ways; (1) most frequently
via low domain or aggregate questionnaire scores; (2) via
additional information provided by their participants (commonly
un-requested comments provided on the back of the
questionnaire, or in accompanying letters); and (3) during
conversations with the trial participant that were prompted by
the act of filling in the questionnaire.
“A couple of times where measurable erm
data… that the doctor had done, showed yeah,
maybe a bit of a slight wobble but everything is
okay. Whereas they’re - according to their erm
quality of life questionnaire, they will sort of say
oh god, it’s all awful and it’s all really getting
worse… that was noted and the patient was
called back in early.” [participant 17; research
nurse]
“People will send their questionnaires back
and sometimes they’ll attach a letter, or... they’ll
write little comments on the back… there’s
been the odd participant erm that’s sent
Inconsistencies in Quality of Life Data Collection
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something back that I’ve sort of read and been
a little bit worried about them.” [participant 20;
trial coordinator]
“When we did the questionnaire, she got
quite upset… so I spent most of the time talking
to her about what help she could, erm, get, and
we, I went online and looked up the number of
the Alzheimer’s Society, and things like that for
her.” [participant 22; research nurse]
Researchers discussed the frequency with which
‘concerning’ data was encountered, variously reporting it as
‘every other week’ (participant 21; trial coordinator), ‘two or
three percent’ (participant 23; data manager) or as
approximately ‘five percent’ (participant 24; research nurse) of
the total volume of HRQL data viewed. Some used less precise
phrases, for example, ‘a couple of times’ (participant 17;
research nurse), or ‘sometimes’ (participant 20; trial
coordinator): 11 interviewees (42%) reported that they had
never come into contact with ‘concerning’ HRQL data.
Action.  The majority of interviewees (n=23, 88%) thought
‘concerning’ data always warranted some form of response. No
consistent way of responding emerged, however, possibly
because interviewees also reported that there were generally
no instructions available on what to do in such a situation. They
therefore reported experience of a range of responses
including the following; calling the trial participant back into
clinic for a further consultation, altering their medication,
offering comfort and, most commonly, referral to their GP
and/or to a specialist health professional (generally following
prior consultation with the participant).
“One consultant called me back in because
the patient had left [the HRQL questionnaire]
with him… and he’d looked at it and was
concerned at what he was seeing, and saying,
‘That’s not the patient that presented to me. We
need to call them back in and we need to,’ you
know, ‘talk to them again’.” [participant 15;
research nurse]
“The patient came back... [they] were advised
over the phone to just change the medication
slightly and increase the frequency of drops
and then the patient came in earlier and was
seen.” [participant 17; research nurse]
“The patient was contacted… The surgery
was contacted. And it has been notified to the
GP as well that, ‘We received this piece of
information from your patient X.’ So, erm, the
GP was aware at that point… that this patient is
in, in such a state.” [participant 19; research
nurse]
No action.  One interviewee reported taking no action when
encountering data indicating poor HRQL. Another described a
strategy that had been implemented in their trial which was
aimed at avoiding the issue altogether, namely, removal at the
outset of questions that were thought likely to lead to the
generation of ‘concerning’ data.
“When they say they haven’t got a really
good quality of life, you think, ‘Oh, dear,’ you
know... not really a lot I can do about that… I’m
just recording what the patient has said.”
[participant 23; data manager]
“Initially, we did have... one section of
questionnaires which was more about, sort of,
depression, erm, and it was decided to remove
those because we didn’t necessarily… like, if
someone put particular answers, we’d have to
deal with that… so we decided to remove
those.” [participant 25; trial coordinator]
Reporting of actions.  Interviewees were asked if
concomitant medicinal interventions, administered as a result
of encountering ‘concerning’ data, would be reported through
existing trial mechanisms. Opinion was divided. Some thought
this data would be automatically captured.
“[the co-intervention] would be entered in the,
in the database of our trial… So, if, if the other
person who’s gonna see the patient the next
time is looking at the data, they will be
collecting that information, they will have that
beforehand, and relate it to the, the records in
the surgery.” [participant 19; research nurse]
Others felt that some trials might find it difficult to fully track
such interventions, especially if the period between follow-up
clinics was long, or the trial involved postal questionnaires.
“You don’t tend to get any information, erm,
coming back from the GP… And I think most
patients, you probably won’t see them again
because some of those questionnaires may be
just a one-off… they might be filling the rest of
them in and sending through the post. So, if it’s
not a follow-up thing where you’re gonna see
the patient again. You might not know… So
that’s become an issue.” [participant 13;
research nurse]
Two interviewees talked explicitly about whether non-
medicinal interventions, for example referral for clinical
psychology or counseling, would be reported/captured: there
was uncertainty over whether this would occur.
“I doubt it whether a… it depends on the
system... there may be referral, like, the doctor,
the GP may say, ‘Referred to the counselor,’…
I don’t know whether I’ll be able to see it. I don’t
know.” [participant 19; research nurse]
Researcher burden
Some interviewees reported feeling emotionally and/or
ethically burdened by the task of HRQL data-collection. This
sense of burden was usually reported in connection with
dealing with HRQL-related participant distress, encountering
Inconsistencies in Quality of Life Data Collection
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e76625
‘concerning’ data, or (predominantly for research nurses)
attempting to resolve the tension between the two roles of
‘researcher’ and ‘health-care practitioner’.
Participant distress.  Our researchers reported frequently
having to deal with patients who were particularly emotional
following HRQL measurement. Some therefore felt
uncomfortable providing HRQL measures that included
questions they knew often distressed patients
“Some of the patients get quite upset,
especially when you ask them about anxiety
and depression… I have had occasions where
patients just burst into tears… it does tend to be
quite an emotional thing for them to, to discuss,
really.” [participant 22; research nurse]
“It’s almost reinforcing all the problems and
some of them have got, you know, ‘is this
affecting your finances’, you know ‘are you
anxious and worried’ and it’s like ‘well yes I
am,’... if they’ve been unwell, sick… you just
sometimes feel like it’s the last thing they need
to be doing.” [participant 5; research nurse]
“I feel really awful because I’m the one who’s
handed them this questionnaire... I don’t want
them to feel, you know, leave feeling depressed
or… feeling a bit worried, because that’s not
what I’m here for.” [participant 11; research
nurse]
Interviewees also reported that they could be emotionally
affected themselves, following such encounters.
“It looked, to me, as a… completely fed up
and frustrated patient, ready to give up life…
and I started shaking when I read it.”
[participant 19; research nurse]
“Some of the more severe ones, or the more
sad ones… you do go home and, and think
about them.” [participant 21; trial coordinator]
“I’m reading what’s happening to these ladies
and gentleman, and it’s, it is heartbreaking. And
I have cried sometimes.” [participant 23; data
manager]
Some reported feeling the weight of responsibility when
having to decide whether, and how, to handle ‘concerning’
data. They described the difficulty in deciding whether or not to
intervene in these situations, and suggested that they did not
always feel prepared or trained to handle such decisions.
“I remember at a steering group meeting,
saying… ‘Well, okay, how would you advise I
make that decision?’ and being told, ‘Well,
you’re not a clinician, you’re not supposed to be
making that decision,’ and me, sort of, saying,
‘Okay, but you’re asking me to!’… So it’s
difficult.” [participant 21; trial coordinator]
Dual-role tension and duty of care.  There were also
reports of burden associated with a perceived tension, for
some interviewees, between their dual professional roles as
health-care practitioners and researchers.
“We're told constantly… recruit, recruit,
recruit... and for commercial trials you have to
hit your targets… [but] you build up that very
close relationship with people and yeah, it’s…
they are patients first.” [participant 17; research
nurse]
“You do feel that, erm, that contradiction
between being a researcher and having to be
quite, erm, detached and it’s data. And, then, a
lot of the patients I know as people, and I’ve
visited them.” [participant 21; trial coordinator]
The majority reported resolving this tension in favour of the
‘patient’ (the trial participant), identifying a perceived duty of
care which directed them to consistently place the needs of the
patient over and above those of the study. Interviewees tended
to justify this position either by appealing to their personal
values, or by invoking the obligations associated with their
profession: for example, ‘make the care of people your first
concern’, from the Nursing and Midwifery Council Code of
Conduct [17].
“I have been in that position and I have been
told that the study comes first [because] that’s
my role… at the end of the day… that’s not how
it works… I am [a] registered nurse… I have to
act upon that as well.” [participant 8; research
nurse]
“You have got this ethical dilemma between
the research and the, and the patient, but your
patient always comes first, so there shouldn’t
really be an ethical dilemma.”[participant 9;
research nurse]
“You have duty of care to that patient… Let
other people worry about the massive numbers
and the quality of the data… Your duty of care
is there and then to that patient.”[participant 24;
research nurse]
There was, however, one individual who held the opposite
view: that their primary responsibility rested with the trial.
“I actually think you’ve got a duty to produce
good research data… I know the impact of
quality of life data… and I’ve seen it go through
NICE [National Institute for Health and Care
Excellence] and I know how important it can
be.” [participant 15; research nurse]
This interviewee felt that their job was to ensure clean data
and that it was the responsibility of those outside of the
research study - the participant’s GP and regular health care
professionals - to monitor and deal with HRQL-related issues,
such as anxiety or depression.
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“They’re in the system, they’re not just seeing
a [research] nurse… I think some people feel
they’re the only person that can pick it up, but if
we all work as a team when we’re all doing our
job, those issues should be picked up as well
elsewhere.” [participant 15; research nurse]
These statements were discussed with other researchers in
subsequent interviews, however, no other individuals
supported this point of view.
Deficiencies in HRQL trial management
Interviewees reported perceived deficiencies in trial
management relating to HRQL data collection and suggested
there were four areas in need of improvement; (1) the provision
of adequate data-collection guidelines; (2) the implementation
of training; (3) the effective transfer of information between the
trial team, the research staff and the trial participants; and, (4)
the attitude of trial management groups (TMGs) to HRQL as an
outcome.
Guidelines.  Interviewees reported they had been given little
guidance either in the trial protocol, or in SOPs, on the
administration of HRQL measurement, and there were no
guidelines on dealing with ‘concerning’ data.
“I don’t think there’s an overall clarity about…
using quality of life measures... [if the patient
writes] additional information [on their
questionnaire], how does that get recorded,
how does that get fed back to the team? What
happens… if you are concerned about
somebody? What’s the process? What level
should we get involved?...speaking to patients
on the phone… what sort of things should we
be checking out to make sure that they are
actually okay?… these sorts of issues aren’t
really covered anywhere.” [participant 20; trial
coordinator]
Interviewees wanted guidelines in these areas, which they
felt might be especially useful for inexperienced researchers.
There was no consensus, however, on the optimal format for
such guidance. The majority supported the reproduction of
HRQL guidelines within the trial protocol, but some felt that the
protocol was not always written in a language that was readily
accessible to them, and instead suggested a role-specific
appendix, or a separate SOP or work instruction.
“All that the nurses have got really is the
protocol, which is… it’s more for the PI
[Principle Investigator], basically, because it’s
so in-depth… and there’s the patient
information sheet which is a whittled down
version of the protocol. And there’s nothing
really in between… for the nurses. There’s no
[specific] guidance for us… So I think
something in the middle would be nice.”
[participant 11; research nurse]
Training.  Interviewees expressed discontent at what they
felt was a general lack of in-trial HRQL training and wanted
improvements in this area.
“I did not have any quality of life training, had
no idea of the importance of quality of life
questionnaires, until I went on this [external
course]... we should have been aware, because
it’s such an important part… I really do wish
that we’d had this training right at the
beginning.” [participant 4; research nurse]
Some felt that HRQL training should be delivered as part of
existing site inductions, and others that an external study day
(or half-day) would better suit their needs. Again, there was a
feeling that training would be particularly useful for junior
researchers. Interviewees were asked what elements they
would like to see included in HRQL training, answers included;
the purpose and importance of HRQL measurement, the
optimal methods of administration, dealing with difficult
situations, counseling distressed participants and dealing with,
and reporting, ‘concerning’ data without introducing bias
(participants 1-9, 11-13, 15, 17-20, 22-25).
Education of data collectors and trial
participants.  Interviewees reported that their trial participants
would sometimes decline to answer HRQL questions that they
regarded as overly intrusive (e.g. surrounding sexual activity)
or struggle to answer sections they regarded as of
questionable relevance to their situation (e.g. questions
surrounding depression given to participants at low risk of the
condition), which might result in missing data.
“The feedback you get is... ‘I can’t
understand why they’re asking me this’…”
[participant 4; research nurse]
“They’re a bit, ‘Oh, well, what relevance has
this got to me having my hip done?’…”
[participant 11; research nurse]
“Usually there’s a lot of, around the sexual
health... part of the, of the form, they do miss
off, especially... They just refuse to answer.”
[participant 23; data manger]
Research nurses suggested that their participants would be
more inclined to answer such questions if they were able to
educate them about the relevance of the individual questions,
and the purpose and importance of HRQL data generally, to
the outcome of the study. Many nurses felt unable to do this,
because they were rarely given this information by the TMG in
the first place.
“We could have done with the training on the
relevance of quality of life much, much earlier
on... I think that would have helped explain the
role of quality of life to patients as well, erm,
because the feedback you get is… ‘I can’t
understand why they’re asking me this,’… so, I
think it’s very important that you educate the
interviewer so that they can explain. [participant
4; research nurse]
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Two possible reasons were suggested for this lack
information transfer. First, that TMGs may believe the majority
of research nurses did not want to be overloaded with
information during trial training and those nurses who wanted
to find out more about the purpose of HRQL measurement
could consult the protocol.
“The only people that were explained stuff
were the GPs... we would tell them what the
study’s about... ‘This is the study.’ ‘This is what
we’re trying to find out…’ But when it came to
the nurses, it wasn’t deemed necessary...
There was a, a copy of the protocol... to find out
more information... you don’t want to bog them
down... you want to make it seem as easy as
possible.” [participant 10; trial coordinator]
Second, that TMGs may assume that HRQL measurement
was entirely straightforward and therefore did not warrant
explanation.
“Quality of life questions. They’re deemed as,
'Well, it’s self-explanatory. You just put it
through and you ask the questions.' Erm and
that, I know, happens.”[participant 10; trial
coordinator]
Attitude to HRQL measurement.  A number of interviewees
suggested that HRQL measurement was not taken seriously
enough by TMGs, stating that they felt HRQL was often
regarded as an ‘add-on’ rather than a valued outcome. Several
stated that improvements in HRQL guidance or training would
only be effective if TMGs adopted an earnest attitude toward
optimal HRQL assessment.
“I think you’d need to have the other things in
place, that quality of life is taken seriously and
is not just thought of as an add-on… and have
a good training plan… so that everybody then
who was on a trial had that information at the
start, they had that training and they had right,
this is our role, this is what we do in a situation
like this. And this is our duty, I think we’d have
to have all of that sorted out before that system
would work and be effective.” [participant 20;
trial coordinator]
Discussion
This study provides insight into the experiences of, and
issues faced by, research nurses, trial coordinators, data
managers and research facilitators involved in the collection of
HRQL data in clinical trials in the UK.
Principal findings
Our results suggest there may be inconsistencies in the
quality of HRQL data collection across, and within, clinical
trials, which has the potential to adversely affect the reliability
and validity of trial results. This variation appears to arise from
sub-optimal standards of HRQL-specific trial protocol content,
training and education.
Standardisation of data-collection processes is a
fundamental aspect of trial design, which is aimed at reducing
bias and measurement variability and maximizing data quality
[10]. Interviewees in our study reported that both between-site
and within-site standardisation was lacking, particularly with
regard to logistical aspects surrounding: the timing of HRQL
assessment (before/during/after the clinic appointment); the
levels of privacy and assistance given to trial participants
completing their questionnaires; and approaches to the
management of missing data. HRQL assessment should
ideally be undertaken at the same pre-specified time points in a
trial, normally prior to clinic appointments, which can have an
undue influence on PROs such as HRQL [18,19]. Our findings
suggest that decisions regarding the timing of HRQL
questionnaire completion can be ad-hoc and, in the absence of
trial-level instructions, have the potential to vary between trial
sites, risking bias. Similarly, our results suggest that the levels
of privacy and assistance afforded to trial participants involved
in HRQL measurement are also inconsistent across study
sites.
Missing data can be a particular problem in trials with a
HRQL outcome, and unlike some clinical outcomes,
retrospective data capture may not be possible [20]. Methods
to minimise missing data should be considered at the design
phase of the trial and implemented in a consistent way [21].
Implementation of such methods were not universally reported
by our interviewees and there were clear examples of
questionable practice. In one trial, it was reported that missing
clinical outcomes were actively pursued whereas absent HRQL
questionnaires or items were not sought at all (participant 20).
This approach may be potentially damaging to the trial as
HRQL data is often not missing at random and may, therefore,
represent a potential source of bias, especially when levels are
high and differ by treatment group [20,22]. In another trial, it
was reported by one interviewee (participant 25) that varying
methods for retrieving missing HRQL data were employed
across opposing arms of the trial, with face-to-face methods
being used for the intervention group and postal methods for
the control, again, such an approach may risk the introduction
of systematic bias.
Our data suggests that inconsistency in HRQL data-
collection methods may stem from a general lack of HRQL or
PRO-specific protocol content, supporting trial documentation
(such as SOP’s), and training and education. In the absence of
such guidance, some interviewees felt they were left to find
their own way of administering PROs, which perhaps explains
the variation in methods employed. It is not clear why PRO
data collection methods were not routinely included in the
protocols of trials where HRQL was a primary, or important
secondary, outcome. As far back as 1997, Fayers and
colleagues [23] released guidelines for protocol writers, which
included specific examples of text aimed at improving HRQL
data-collection. Other authors have since produced guidelines
that also address aspects of this area, although most are
limited by a lack of systematic development or stakeholder
involvement [18,19,21,24-33]. More recently, the US Food and
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Drug Administration [8] and the Centre for Medical Technology
Policy [34] have published guidance documents containing
recommendations geared towards the management of missing
data and aimed at optimising the implementation of PROs such
as HRQL. Moreover, these guidelines specifically promote the
training and education of both trial researchers and participants
as a key element of clinical trial quality control.
There are, however, some limitations with the current PRO
guidance documents. Data-collection is generally not the focus
of any paper, meaning that recommendations in this area can
be sparse when they appear. In addition, there is no clear
consensus in the literature, therefore, differing guidelines are
spread across a number of publications [35]. This may, in part,
explain why our findings suggest that recommendations are not
filtering down to the level of local trial site personnel. Our
interviewees also suggested the reason for this lack of
information cascade might be that trial management teams did
not always feel specific guidance or training was warranted,
either because HRQL data-collection was deemed to be self-
explanatory, or that the protocol would already provide all
necessary information and further guidelines might overload
research nurses with additional (and presumably unnecessary)
content. Our research nurse interviewees disagreed with these
sentiments, appearing to welcome more information on all
aspects of HRQL measurement, which they felt was not always
straightforward and could present a considerable emotional
and/or ethical burden. They also highlighted that the protocols
they generally worked with rarely contained HRQL-specific
information that was adequate to support their needs, and were
not always pitched at a level that was readily accessible to
them. Finally, it is of course possible that HRQL-specific
information was available in at least some trial protocols, but
that our interviewees could not accurately recall its content.
Evaluation of the quality of HRQL protocol content, and the
extent to which relevant guidelines are internalised by trial staff,
warrants further research.
Our other main finding surrounds the previously unreported
phenomenon of ‘concerning’ data, which was described as
data that raised concerns about the participant’s wellbeing.
‘Concerning’ data, although arising infrequently, was reported
to present significant challenges for those who dealt with it,
with little or no guidance provided by their TMG on how to
manage it. Some research nurses reported feeling a degree of
tension between their dual roles as a researcher and
practitioner when faced with such data. They acknowledged a
professional obligation to make any concern for the trial
participant their first priority, but as researchers, they also
recognised a duty to maintain the integrity of the trial. This
dual-role tension has been discussed elsewhere [36-39]. It can
be problematic, as it has been suggested that the need to
collect ‘clean’ data and minimise withdrawals has the potential
to disproportionately influence decisions related to the
wellbeing of the participant [36]. This view was not supported
by our data, with all but one informant reporting that they
consistently prioritised the wellbeing of the participant over the
needs of the trial. This behavior demonstrates a widespread
endorsement by our interviewees of the first principle of ‘good
clinical practice’ as outlined in European Union directive
2005/28/EC: “The rights, safety and well being of the trial
subjects shall prevail over the interests of science and society”.
[40] As our findings suggest, however, this approach was not
without its problems. In the presence of ‘concerning’ data (and
in the absence of appropriate guidance), several interviewees
reported the provision of non-standardised co-interventions,
administered, in good faith, to assist the trial participant in
distress. Some interventions, especially those involving onward
referral or non-medicinal treatments for example, may not be
captured by standard trial reporting systems, which could lead
to co-intervention bias [11].
Strengths and limitations of the study
The strength of this study is its use of qualitative methods to
provide an insight into the previously unexplored issues
surrounding PRO data-collection in UK-based clinical trials,
with a specific focus on HRQL. Our use of semi-structured
interviews allowed the exploration of several ‘core’ topics with
each of our interviewees, but still allowed scope to investigate
novel themes as they emerged. The validation of interview
summaries by our study participants, and the triangulation of
analysis by four different researchers are further strengths and
lend credibility to the data.
A limitation was that the interviewer had prior knowledge of
some of the issues that were likely to be discussed, which
could have influenced data collection. We attempted to mitigate
for this through the use of a topic guide that encouraged the
use of non-leading questions and through other credibility
enhancing processes, including regular team meetings aimed
at facilitating reflexivity, peer review of verbatim interview
transcripts and formal triangulation of coding. The recruitment
methods meant the participants in this study were self-
selected. The results we have presented could be particular to
this (UK-based) sample and may not be readily transferred to
dissimilar groups and research contexts. The interviewees
were, however, recruited from a variety of settings in both
primary and secondary care, and were selected to capture a
range professional backgrounds and levels of experience.
Conclusions
This is the first study to investigate the views of research
nurses, trial coordinators, data managers and research
facilitators involved in HRQL data collection. Our findings
suggest that there are inconsistencies in the standards of
HRQL data collection in some trials, which may affect the
reliability and validity of trial data and could lead to biased
results. These inconsistencies may stem from a general lack of
HRQL-specific protocol content, training and education within
trials. We also found that research nurses, and to a lesser
extent data managers, are sometimes exposed to HRQL data
that cause them to become concerned for the wellbeing of the
trial participant. Again, there appears to be a lack of protocol
content and training on how to recognise and respond to such
data. This lack of guidance risks the provision of co-
interventions, which may remain un-reported and have the
potential to introduce bias. Further research, using both
qualitative and quantitative methods, and undertaken
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internationally, is needed to determine the extent of each of the
problems highlighted in this study.
Our findings underline the need for improved guidance on
PRO data collection in trials and clearer, more detailed,
descriptions of how to collect and manage these data in trial
protocols and SOPs. Ideally, current guidance documents
should be supplanted with internationally endorsed consensus
guidelines, specifically tailored to the promotion of best practice
in PRO data-collection. In the meantime, trialists should utilise
existing PRO and HRQL-specific data-collection
recommendations [8,18,19,21,23-34] to inform the trial design
process, alongside more general high quality protocol
guidelines such as the SPIRIT 2013 statement [10,41]. Trial
management teams have a responsibility to provide local site
personal with protocol content and supporting trial
documentation, alongside trial training and education, which
aids optimal collection of both standard and ‘concerning’ PRO
data, whilst minimising the risk of bias.
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